Lipocine Inc. 8-K

What Happened Lipocine Inc. (LPCN) filed a Form 8-K on January 20, 2026 to announce that it has completed enrollment and dosing in its Phase 3 clinical trial of LPCN 1154 for postpartum depression (PPD). The company furnished a press release announcing this milestone as Exhibit 99.1 to the 8-K.

Key Details

• The 8-K reporting date: January 20, 2026.
• Event reported under Item 8.01: completion of enrollment and dosing in the Phase 3 LPCN 1154 PPD trial.
• The press release announcing the milestone is filed as Exhibit 99.1 and is incorporated by reference.
• The filing also includes the required Inline XBRL cover page (Exhibit 104).

Why It Matters Completion of enrollment and dosing is a key clinical development milestone that moves LPCN 1154 into the next stage of the trial process (data follow-up and analysis). For investors, this confirms the trial is fully enrolled and active completion reduces enrollment risk and can clarify the expected timing for upcoming data readouts or regulatory steps, though the company did not announce any efficacy or safety results in this filing.